Find a study
Browse recruiting studies near you — free to check, always your choice.
30 studies
Recruiting now, in plain language. Every study is watched over by an independent ethics board.
- Rheumatoid arthritis
Oral Versus Intramuscular Steroid Use to Control Rheumatoid Arthritis Flares
Comparing pills versus shots of steroids to control rheumatoid arthritis flares
📍 Sunnybrook Health Sciences Centre · Toronto, Ontario · Get directions →
People living with rheumatoid arthritis (RA) often experience flares-periods where their symptoms suddenly get worse. These flares can cause significant pain, make it harder to move and do daily activities, and lower overall quality of life.
- Rheumatoid arthritis
Dynamic Treatment Regiments for Glucocorticoid Tapering
Studying how people with rheumatoid arthritis respond to tapering steroid medicine
📍 VA Ann Arbor Healthcare System, Ann Arbor, MI · Ann Arbor, MI · +1 more US site · Get directions →
The purpose of this clinical trial is to better understand how people with rheumatoid arthritis (RA) respond to gradual dose reduction, or "tapering", of steroid medications like prednisone. Some people with RA have symptoms when steroid dose is reduced, while others don't.
- Rheumatoid arthritis
AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.
Testing safety and effects of cord blood immune cells plus rituximab for relapsing rheumatoid
📍 Artiva Investigational Site Tuscaloosa · Tuscaloosa, AL · +30 more US sites · Get directions →
A Basket Trial of Refractory Rheumatoid Arthritis (RA), Sjögren's Disease (SjD), Idiopathic Inflammatory Myopathies (IIMs) and Systemic Sclerosis (SSc) subjects to evaluate the safety and efficacy of AlloNK, a non-genetically modified allogeneic NK cell, in combination with rituximab.
- Rheumatoid arthritis
A Study to Assess the Safety and Efficacy of Different Doses of ELV001 to Treat Active Rheumatoid Arthritis in Patients With an Inadequate Response to Methotrexate and Tumor Necrosis Factor Inhibition (START SYNERGY)
Testing different doses of ELV001 for rheumatoid arthritis symptoms
📍 Arizona Arthritis & Rheumatology Associates · Gilbert, AZ · +21 more US sites · Get directions →
This is a Phase 2 randomized, double-blind, placebo-controlled study with a total duration of 32 weeks from Screening to End-of-Study (EOS) Visit. Approximately 180 participants are planned to be enrolled.
- Rheumatoid arthritis
Advanced Therapeutics in Rheumatoid Arthritis (RA)
Tracking how long two rheumatoid arthritis treatments are kept in adults
📍 Rheumatology Clinic, St. Joseph's Health Care · London, Ontario · Get directions →
This study will evaluate the retention rates of two advanced therapies, Tumour Necrosis Factor (TNF) and Janus kinase inhibitor (JAK) in the treatment of adults with Rheumatoid Arthritis (RA) over a two year period. It will also examine the ability to embed a clinical trial in a clinical situation using an electronic medical record (EMR).
- Heart / cardiovascular disease
Improving Coronary Vascular Health in Women
Testing whether blood flow in heart arteries can be improved in women with HIV
📍 Massachusetts General Hospital · Boston, MA · Get directions →
Women with HIV have an increased risk of having a myocardial infarction (heart attack) as compared to women without HIV. One of the mechanisms underlying the increased risk of myocardial infarction among women with HIV may involve reduced ability to increase blood flow through large and small coronary arteries at times when increased flow of oxygen-carrying blood is needed.
- Rheumatoid arthritis
A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)
Testing how safe and tolerable an immune-cell treatment is for rheumatoid arthritis
📍 Nkarta Investigational Site · Orange, CA · +14 more US sites · Get directions →
This is a Phase 1/2, open-label, multi-center, multi-cohort, non-randomized dose escalation and dose expansion basket study to determine the safety and tolerability of NKX019 (allogeneic CAR NK cells targeting CD19) in participants with autoimmune diseases.
- Rheumatoid arthritis
"Effect of Vitamin E (α-Tocopherol) on Clinical Activity and Inflammation in Rheumatoid Arthritis"
Testing whether vitamin E lowers inflammation and symptoms in rheumatoid arthritis
📍 Civil Hospital of Guadalajara · Guadalajara, Jalisco · Get directions →
The objective of this clinical trial is to determine whether α-tocopherol (vitamin E) supplementation decreases inflammation and clinical activity in patients with rheumatoid arthritis (RA).The main questions to be answered are: * Is supplementation with vitamin E (α-tocopherol) for one month associated with decreased clinical activity and inflammation in patients with RA? Researchers will compare α-tocopherol with a placebo (a look-alike substance containing no active ingredient) to see if α-tocopherol effectively reduces inflammation and clinical activity in patients with rheumatoid arthritis.
- Rheumatoid arthritis
A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis
Testing targeted treatments for people with moderate to severe rheumatoid arthritis
📍 Sun Valley Arthritis Center /ID# 278331 · Peoria, AZ · +39 more US sites · Get directions →
Rheumatoid Arthritis (RA) is a chronic inflammatory disease causing pain, stiffness, swelling and loss of joint function. This study will evaluate the efficacy and safety of targeted therapies through a series of substudies for the treatment of moderately to severely active Rheumatoid Arthritis (RA).
- Heart / cardiovascular diseaseLupus (SLE)
The Role of Anifrolumab in Improving Markers of Vascular Risk in Patients With Systemic Lupus Erythematosus (SLE) - IFN-CVD
Testing whether anifrolumab improves blood vessel risk markers in lupus
📍 National Institutes of Health Clinical Center · Bethesda, MD · Get directions →
Background: People with systemic lupus erythematosus (SLE) are at risk of developing complications in their blood vessels. This can increase the risk of heart attacks or stroke.
- Lupus (SLE)Rheumatoid arthritisCrohn's / ulcerative colitis (IBD)
COVID-19 Booster and IIV Schedule in Immunocompromised Hosts
Testing COVID-19 booster and flu vaccine schedules in people with lupus, rheumatoid arthritis, or
📍 Maisonneuve -Rosemont Installation · Montreal, Quebec · Get directions →
The goal of this pragmatic embedded open-label, 2 x 2 factorial phase II randomized controlled trial is to evaluate strategies to improve COVID-19 booster and influenza vaccine immunogenicity in people living with immunocompromising conditions (PLIC). The main questions it aims to answer are: 1.
- Rheumatoid arthritis
An Extension Study to Assess Long-Term Safety and Efficacy of Afimkibart in Participants With Rheumatoid Arthritis
Testing the long-term safety and results of afimkibart in rheumatoid arthritis
📍 DM Clinical Research · Tomball, TX · Get directions →
The study will evaluate the long-term safety and efficacy of Afimkibart (also known as RO7790121) in participants with moderate to severe Rheumatoid Arthritis (RA) who have an inadequate response or intolerance to tumor necrosis factor (TNF) and/or Janus kinase (JAK) inhibitors, and who were previously treated with Afimkibart.
- Rheumatoid arthritis
A Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Rheumatoid Arthritis Who Have Not Responded to or Who Cannot Tolerate Tumor Necrosis Factor (TNF) and/or Janus Kinase (JAK Inhibitors)
Testing a new medicine versus placebo for rheumatoid arthritis after TNF or JAK drugs didn’t work
📍 SunValley Arthritis Center Ltd. · Peoria, AZ · +11 more US sites · Get directions →
This study will assess the efficacy and safety of Afimkibart (also known as RO7790121) compared with placebo in participants with moderate to severe rheumatoid arthritis (RA) who have an inadequate response or intolerance to TNF and/or JAK inhibitors.
- Lupus (SLE)Rheumatoid arthritis
A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases
Testing how safe inebilizumab and blinatumomab are in adults with lupus or rheumatoid arthritis
📍 HonorHealth Research and Innovation Institute · Scottsdale, AZ · +16 more US sites · Get directions →
The main objective is to assess the safety and tolerability of inebilizumab in adult participants with active and refractory systemic lupus erythematosus (SLE) with nephritis (Subprotocol A) and to assess the safety and tolerability of subcutaneous (SC) blinatumomab in adult participants with active and refractory SLE with and without nephritis (Subprotocol B Part A) and in adult participants with active refractory rheumatoid arthritis (RA) (Subprotocol C Part A). The trial will also assess the efficacy of SC blinatumomab in adult participants with active and refractory SLE with and without nephritis (Subprotocol B Part B and Subprotocol C Part B).
- Obesity / overweightHeart / cardiovascular disease
A Phase 2 Study to Evaluate the Pharmacodynamics, Safety and Tolerability of BGE-102 in Participants With Obesity and Cardiovascular Risk Factors
Testing how BGE-102 affects inflammation blood tests and safety in people with obesity and heart
📍 Site 108 · Chandler, AZ · +11 more US sites · Get directions →
The purpose of this study is to learn about the effects of BGE-102 on blood biomarkers including hsCRP, which is a lab value used to measure inflammation. BGE-102 decreases inflammation which may improve obesity and cardiovascular health.
- Obesity / overweightHeart / cardiovascular disease
Mechanisms of Semaglutide Therapy in Heart Failure Patients
Testing how semaglutide works in people with heart failure and obesity
📍 Greenstone Biosciences · Palo Alto, CA · +1 more US site · Get directions →
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist, primarily used for treatment of type-2 diabetes mellitus. GLP-1 receptors are present on pancreatic islet β-cells, δ-cells and α-cells.
- Rheumatoid arthritis
A Dose Response Study to Evaluate the Efficacy and Safety of Oral AP1189 Administered in Disease-Modifying Anti-Rheumatic Drug (DMARD) naïve Participants Participants With Early Rheumatoid Arthritis
Testing different doses of an oral medicine with methotrexate in early rheumatoid arthritis
📍 Nouvelle Clinical Research LLC · Cutler Bay, FL · +2 more US sites · Get directions →
The study is a randomized, double blind, placebo-controlled, dose response, phase II, multicentre trial to evaluate the efficacy and safety of oral AP1189 administered at the doses of 40, 70, or 100 mg for 12 weeks in combination with methotrexate, in DMARD-naïve participants with early rheumatoid arthritis and active inflammation.
- Heart / cardiovascular disease💵 May compensate
Canagliflozin Targeting Vascular Inflammation
Testing canagliflozin to reduce blood vessel inflammation in cardiovascular disease
📍 University of Ottawa Heart Institute · Ottawa, Ontario · Get directions →
CANTOR SING is a pilot single center double blinded randomized study. The investigators will compare the effect of canagliflozin (300 mg daily - intervention arm) vs.
- Heart / cardiovascular disease
Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)
Testing a medicine to see its cardiovascular effects in adults on dialysis
📍 Nephrology of North Alabama · Decatur, AL · +39 more US sites · Get directions →
This is a two-part, phase 2b and phase 3 combined prospective, interventional, multicenter, randomized, double-blind, placebo-controlled study. Part 1: Phase 2b is a dose-finding study for CSL300 vs placebo.
- Rheumatoid arthritis
A Study to Investigate Efficacy and Safety of AZD1163 in Participants With Rheumatoid Arthritis
Testing how well and how safely AZD1163 works for people with rheumatoid arthritis
📍 Research Site · Glendale, AZ · +27 more US sites · Get directions →
Phase II study in participants with moderately-to-severely active rheumatoid Arthritis (RA) to evaluate efficacy and safety of AZD1163.
- Obesity / overweightType 2 diabetesHeart / cardiovascular disease
Pioglitazone on Heart Failure in Type-2 Diabetes Mellitus Participants
Testing the diabetes medicine pioglitazone in people with type 2 diabetes, obesity, and heart
📍 Texas Diabetes Institute/UH · San Antonio, TX · Get directions →
Our goal of the study is to learn the effects of the diabetes medication named Pioglitazone, in type-2 diabetic obese participants with Heart failure. The main question it aims to answer are: 1.
- Rheumatoid arthritis
Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT
Testing reduced-intensity transplant approaches for people with rheumatoid arthritis
📍 UPMC Children's Hospital of Pittsburgh · Pittsburgh, PA · Get directions →
The objective of this study is to evaluate the efficacy of using a reduced-intensity condition (RIC) regimen with umbilical cord blood transplant (UCBT), double cord UCBT, matched unrelated donor (MUD) bone marrow transplant (BMT) or peripheral blood stem cell transplant (PBSCT) in patients with non-malignant disorders that are amenable to treatment with hematopoietic stem cell transplant (HSCT). After transplant, subjects will be followed for late effects and for ongoing graft success.
- Heart / cardiovascular diseaseDementia / Alzheimer's
Pragmatic Evaluation of Events And Benefits of Lipid-lowering in Older Adults
Testing whether lowering cholesterol in older adults affects heart and memory outcomes
📍 University of Alabama at Birmingham · Birmingham, AL · +37 more US sites · Get directions →
PREVENTABLE is a multi-center, randomized, parallel group, placebo-controlled superiority study. Participants will be randomized 1:1 to atorvastatin 40 mg or placebo.
- Heart / cardiovascular disease
Ertugliflozin in Chronic Heart Failure
Testing ertugliflozin and other medicines for heart failure symptoms
📍 Yale School of Medicine · New Haven, CT · Get directions →
The purpose of this study is to determine the effects on heart failure signs and symptoms of the use of either ertugliflozin, metolazone or placebo, in conjunction with intravenous loop diuretic use in acute settings and chronic oral loop diuretic therapy. There are two general purposes for this study.
- Heart / cardiovascular disease
Mesenchymal Stem Cells for the Treatment of Various Chronic and Acute Conditions
Testing stem cell treatment for safety and effects on heart disease
📍 Southern California Hospital at Culver City / Southern California Hospital at Hollywood / Multiple US-based Sub-Investigator Sites · Culver City, CA · Get directions →
This multi-arm, multi-site study investigates the safety, tolerability, and efficacy of stem cell therapy for the treatment of various acute and chronic conditions. Clinically observed initial findings and an extensive body of research indicate regenerative treatments are both safe and effective for the treatment of multiple conditions.
- Heart / cardiovascular diseaseHigh blood pressure
Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)
Studying how vitamin C affects blood vessel function in obese adults with insulin resistance and
📍 University of Kansas Medical Center · Kansas City, KS · Get directions →
The main purpose of research is to examine and understanding the development of hypertension in obese adults with insulin resistance. Findings from our studies will identify unique mechanisms that can be targeted to limit increases in vascular dysfunction and reduce the excessively high prevalence of hypertension and risk for cardiovascular disease (CVD).
- Obesity / overweightHeart / cardiovascular diseaseHigh blood pressure
PRECISION-BP: Precision Chronopharamacotherapy Targeting NP-RAAS-BP Rhythm Axis
Testing timing of blood pressure medicines in people with obesity and high blood pressure
📍 University of Alabama at Birmingham · Birmingham, AL · Get directions →
Obese individuals have a higher prevalence of nocturnal hypertension and non-dipping blood pressure (BP). These conditions are associated with an increased risk of cardiovascular (CV) events and death.
- Type 2 diabetesHeart / cardiovascular disease
Effect of Tirzepatide on Progression of Coronary Atherosclerosis Using MDCT
Testing tirzepatide to see if it slows plaque buildup in heart arteries in people with type 2
📍 Lundquist Institute for Biomedical Innovation at Harbor UCLA Medical Center (The Lundquist Institute) · Torrance, CA · Get directions →
A multi-center, randomized, double-blind, placebo-controlled, parallel-group phase IV Study evaluating the effects of tirzepatide on atherosclerotic plaque progression assessed by coronary computed tomography angiography (CCTA) in participants with a diagnosis of type II Diabetes (T2DM) and atherosclerosis.
- Heart / cardiovascular diseaseKidney disease
Effect of Dapagliflozin on Metabolomics and Cardiac Mechanics in Chronic Kidney Disease
Testing dapagliflozin with standard care on heart and lung function and blood metabolites in chronic
📍 Northwestern University · Chicago, IL · Get directions →
The goal of this study is to better understand the effects of a sodium-glucose transport protein 2 inhibitor, dapagliflozin, added on to standard of care on heart and lung function and circulating metabolites (substances created when our bodies break down food, drugs, or its own tissues) in patients with chronic kidney disease.
- Obesity / overweightHeart / cardiovascular disease
Effects of Tirzepatide on Muscle and Vascular Health in Obese Older Adults
Testing tirzepatide to see effects on muscle and blood vessels in older adults with obesity and
📍 University of Texas Health Science Center at San Antonio · San Antonio, TX · Get directions →
Obesity and type 2 diabetes mellitus (T2DM) represent major public health concerns in the aging community. Tirzepatide, a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist recently approved for the treatment of T2DM and obesity has been shown to be effective at reducing weight, improving markers of T2DM control, and improving cardiovascular health.